SCHEMBL1765997

SCHEMBL1765997

CCCc1cc(C(=O)CCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C(C)C)ccc1OCC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.51
PPARA Q07869 13/20 0.51
PPARG P37231 9/20 0.51
FFAR1 O14842 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12732411 0.94 PPARD (0.44) PPARDPPARAPPARGFFAR1
SCHEMBL30003549 0.91 PPARD (0.44) PPARDPPARAPPARGFFAR1
SCHEMBL24742081 0.91 PPARD (0.44) PPARDPPARAPPARGFFAR1
SCHEMBL1765842 0.90 PPARD (0.49) PPARDPPARAPPARGFFAR1
SCHEMBL1673096 0.90 PPARD (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL1765890 0.89 PPARD (0.53) PPARDPPARAPPARGFFAR1
SCHEMBL2462565 0.88 PPARD (0.56) PPARDPPARAPPARGFFAR1
SCHEMBL2466344 0.88 PPARD (0.51) PPARDPPARAPPARGFFAR1
SCHEMBL1766000 0.86 PPARD (0.40) PPARDPPARAPPARGFFAR1
SCHEMBL12938302 0.84 PPARD (0.49) PPARDPPARAPPARGFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US claimed
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
EP-1424330-B1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO (JP) 2011-09-28 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US disclosed
US-7648999-B2 Activator for peroxisome proliferator-activated receptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2010-01-19 US disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-7265137-B2 Activator of peroxisome proliferator-activated re-ceptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2007-09-04 US disclosed
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2005-03-10 US disclosed
EP-1424330-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO., LTD. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885PPARG 1/4885
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885PPARG 1/4885
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.